A novel senescence-associated LncRNA signature predicts the prognosis and tumor microenvironment of patients with colorectal cancer: a bioinformatics analysis

Abstract

Background: Accumulating evidence suggests that cellular senescence promotes tumor formation and that long non-coding RNAs (lncRNAs) expression predicts tumor prognosis. However, senescence-related variables, particularly lncRNAs, are still largely unknown. Therefore, the present study developed a novel senescence-associated lncRNA signature to predict colorectal cancer (CRC) prognosis.Methods: A co-expression network of senescence-associated mRNAs and lncRNAs was built using RNAsequence data from The Cancer Genome Atlas (TCGA). By using the prognosis outcomes data of overall survival (OS) and disease-free survival (DFS) from TCGA, we constructed a prognostic senescenceassociated lncRNA signature (SenALSig). The OS and DFS were compared between the low-and high-risk groups defined by SenALSig. A single-sample gene set enrichment analysis (ssGSEA) and CIBERSORT algorithm were used to investigate the relationship between the predictive signature and immune status.Finally, the relationship between SenALSig and drug treatment options was investigated. An independent CRC cohort and three CRC cell lines were recruited to perform real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) analysis to validate the results discovered in silico.Results: A prognostic risk model consisting of six senescence-associated lncRNAs was constructed, including SNHG16, AL590483.1, ZEB1-AS1, AC107375.1, AC068580.3, and AC147067.1. High-risk scores according to the SenALSig were significantly associated with poor OS (hazard ratio =1.218, 95% confidence interval: 1.140-1.301; P<0.001). The model's accuracy was further supported by receiver operating characteristic (ROC) curves (the area under the curve is 0.714) and a principal component analysis (PCA). In univariate and multivariate Cox regression analyses, SenALSig was further found to be a prognostic factor independent of other clinical factors. Furthermore, we discovered that immune checkpoint expression and

Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review)

“…It was also revealed that SNHG16 may serve a contributory role in the proliferation, migration and EMT of CRC cells through the miR-124-3p/MCP-1 axis ( 176 ). Some bioinformatics analyses also reached a similar conclusion, in that SNHG16 may have an important role in CRC ( 175 , 180 ). In particular, SNHG16 has been reported to be closely associated with autophagy in CRC ( 175 , 181 ).…”

A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma

“…This shows that senescent cells in TME are helpful and as valuable as other biomarkers in predicting prognosis and estimating the efficacy of immunotherapy of LUAD. Interestingly, other studies have also focused on the contribution of cellular senescence-associated LncRNAs to tumor prognosis in tumors including liver ( Huang et al, 2022a ), colorectal ( Huang et al, 2022b ), and gastric ( Wang et al, 2022 ) cancers. These studies have similar AUC values to the time-dependent ROC curves of our model and importantly illustrate the contribution of senescent cells to the tumor microenvironment.…”

Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma

“…According to previous studies, lncRNAs are versatile molecules involved in various tumorigenic processes and offer the possibility of being used as biomarkers [ 9 , 10 ]. In patients with colorectal cancer (CRC), stomach adenocarcinoma, or Lung adenocarcinoma (LUAD), senescence-related lncRNA models have been developed and have certain predictive values [ 11 , 12 , 13 ]. However, the signature of senescence-related lncRNAs has not yet been established and applied to the prognosis prediction and clinical treatment of SKCM patients.…”